Lack of Correlations among Histopathological Parameters, Ki-67 Proliferation Index and Prognosis in Pheochromocytoma Patients

  • Ocal, Irfan (Departmant of Pathology, Katip Celebi University Ataturk Education and Research Hospital) ;
  • Avci, Arzu (Departmant of Pathology, Katip Celebi University Ataturk Education and Research Hospital) ;
  • Cakalagaoglu, Fulya (Departmant of Pathology, Katip Celebi University Ataturk Education and Research Hospital) ;
  • Can, Huseyin (Departmant of Pathology, Katip Celebi University Ataturk Education and Research Hospital)
  • Published : 2014.02.28


Background: In this study prognostic correlations of histopathologic parameters and the Ki-67 proliferation index and as well as the diagnostic value of immunohistochemical markers in pheochromocytomas were evaluated. Materials and Methods: A total of 22 patients diagnosed with a pheochromocytoma between 2000-2010 in Izmir Katip Celebi University Ataturk Training and Research Hospital were included. Diagnostic value of the PASS scoring system, and prognostic correlations of histopathologic parameters and Ki-67 proliferation index were investigated. SPSS for Windows 17.0 software was used for statistical analysis. Results: There was no statistically significant correlation between recurrence and clinicopathologic parameters or the PASS score (PASS>4). In addition, there were no statistically significant correlations between PASS score and clinicopathologic parameters, such as diameter (5 cm), weight (>100g), gender (female/male ratio) and age (25-45/45-55/>55). Besides, there were no significant correlation between diameter and clinicopathological parameters and also recurrence. However, there was a statistically significant correlation between Ki-67 proliferation index and capsule invasion (p=0.047). Conclusions: Some but not most of the findings in our study were concordant with the literature. To clarify relationships, investigations with standard scoring systems which are not affected by subjective factors and feature appropriate histopathological criteria should be made on larger study groups.


  1. Agarwal A, Mehrotra PK, Jain M, et al (2010). Size of the tumor and Pheochromocytoma of the Adrenal Gland Scaled Score (PASS): Can They Predict Malignancy? World J Surg, 34, 3022-8.
  2. Clarke MR, Weyant RJ, Watson CG, et al (1998). Prognostic markers in pheochromocytoma. Hum Pathol, 29, 522-6.
  3. DeLellis RA, Lloyd RV, Heitz PU, et al (2004). World Health Organization Classification of Tumours Pathology & Genetics. Tumours of Endocrine Organs, 151-5.
  4. de Wailly P, Oragano L, Rade F, et al (2012). Malignant pheochromocytoma: new malignancy criteria. Langenbecks Arch Surg, 397, 239-46.
  5. Ernest E. Lack (2007). Tumors of the adrenal gland. In 'Diagnostic Histopathology of Tumors 3rd Edition', Eds Christopher D.M. Fletcher. Elsevier Ltd, Philadelphia pp 1109-15.
  6. Harrison LE, Gaudin PB, Brennan MF (1999). Pathologic features os prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg, 134, 181-5.
  7. Kimura N, Miura W, Noshiro T, et al (1994). Ki-67 is an indicator of progression in neuroendocrine tumours. Endocr Pathol, 5, 223-8.
  8. Linnoila RI, Keiser HR, Steinberg SM, et al (1990). Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Patol, 21, 1168-80.
  9. Nagura S, Katoh R, Kawaoi A, et al (1999). Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas. Mod Pathol, 12, 1107-11.
  10. Rosai J (2011). Pheochromocytoma. In 'Surgical Pathology 10th Edition', Eds Rosai and Ackermans. MOSBY Elsevier Inc. pp 1076-8.
  11. Strong VE, Kennedy T, Al-Ahmadie H, et al (2008). Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery, 143, 759-68.
  12. Szalat A, Fraenkel M, Doviner V, et al (2011). Malignant pheochromocytoma: Predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center. Endocrine, 39, 160-6.
  13. Thompson LD (2002). Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol, 26, 551-66.
  14. van der Harst E, Bruining HA, Jaap Bonjer H, et al (2000). Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? J Pathol, 191, 175-80.<175::AID-PATH615>3.0.CO;2-Z
  15. Wu D, Tischler AS, Lloyd RV, et al (2009). Observer variation in the application of the pheochromocytoma of adrenal Gland Scaled Score. Am J Surg Pathol, 33, 599-608.

Cited by

  1. Prognostic Factors in Oligodendrogliomas: a Clinical Study of Twenty-Five Consecutive Patients vol.16, pp.13, 2015,
  2. Pheochromocytoma multisystem crisis treated with emergency surgery: a case report and literature review vol.8, pp.1, 2015,
  3. The Value of Histological Algorithms to Predict the Malignancy Potential of Pheochromocytomas and Abdominal Paragangliomas—A Meta-Analysis and Systematic Review of the Literature vol.11, pp.2, 2019,